GHK-Cu vs SS-31
Research Verdict
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for Barth syndrome; choose GHK-Cu only for skin and matrix-remodeling questions.
Quick Answers
Which is better, GHK-Cu or SS-31?
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for Barth syndrome; choose GHK-Cu only for skin and matrix-remodeling questions.
What is the key difference between GHK-Cu and SS-31?
SS-31 targets inner mitochondrial membrane cardiolipin for cardiac and mitochondrial diseases; GHK-Cu targets extracellular matrix remodeling for skin repair - non-overlapping tissue targets and mechanisms.
Evidence Comparison
Elamipretide has accelerated FDA approval for a narrow Barth-syndrome population, based on a 12-patient program with negative randomized primary endpoints and supportive muscle-strength/open-label evidence. GHK-Cu has small independent human skin studies. The evidence applies to different tissues and cannot be compared as a shared treatment claim.
Evidence Context Favoring GHK-Cu
Skin rejuvenation and collagen research where topical human efficacy data matters.
Evidence Context Favoring SS-31
Barth syndrome or cardiolipin-targeted mitochondrial research; approval does not establish heart-failure or longevity benefit.
Side-by-Side Snapshot
| Evidence grade | GHK-Cu: Level B SS-31: Level B |
|---|---|
| Research status | GHK-Cu: Phase 2 SS-31: FDA Approved |
| Primary category | GHK-Cu: Skin & Beauty SS-31: Anti-Aging & Longevity |
| Cited studies | GHK-Cu: 6 SS-31: 6 |